December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Faeth Therapeutics, Inc. - Common Stock (NQ:FTH)

24.82 -2.07 (-7.70%)
Delayed Quote Updated: 2:53 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Faeth Therapeutics, Inc. - Common Stock

News headline image
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout ↗
Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The... 
Via MarketBeat
News headline image
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Faeth Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.